A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
Completed · Phase 2
Conditions studied: Solid Cancer
In brief
The purpose of this study is to enable participants, currently receiving regorafenib in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. Patients participating in this study will be observed to collect information on how safe the drugs are and how this treatment is tolerated.
Key facts
- Study ID
- NCT03890731
- Run by
- Bayer
- People needed
- 6
- Starts
- 2019-04-02
- Expected to finish
- 2023-02-28
- Last updated by the study team
- 2024-04-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participant must be age-eligible in the feeder study at the time of signing the informed consent.
- Participant is currently participating in any Bayer-sponsored regorafenib study and is receiving study treatment.
- Participant is currently benefiting from treatment with regorafenib monotherapy and meets criteria to initiate a subsequent cycle of therapy, as determined by the guidelines of the feeder protocol.
- Any ongoing adverse events that require temporary treatment interruption must be resolved to baseline grade or assessed as stable and not requiring further treatment interruption by the investigator.
You may not qualify if…
- Medical reasons not to start the next treatment cycle in the respective feeder
- Pregnancy
Where it is running
- Tampa General Medical Group — Tampa, Florida, United States
- Eberhard-Karls-Universität Tübingen — Tübingen, Baden-Wurttemberg, Germany
- Universitätsklinikum Köln — Cologne, North Rhine-Westphalia, Germany
- A.O.U. Careggi — Florence, Tuscany, Italy
- Saiseikai Utsunomiya Hospital — Utsunomiya, Tochigi, Japan
- Mount Vernon Hospital — Northwood, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.